Nanoparticle-siRNA Conjugates
The main challenges facing the application of siRNA therapeutics include the stability and effective delivery of siRNA in vivo. Important advances in nanotechnology have greatly facilitated the development of efficient siRNA delivery systems.
Relying on state-of-the-art biochemical facilities and years of experience in providing high-quality bioconjugate complexes, BOC RNA can provide you with custom nanoparticle-siRNA conjugate services with flexibility, repeatability and quality assurance.
Types of Nanocarriers
Particle Types | Key Features and Advantages |
Organic Nanoparticles | |
Lipid-based nanocarriers | - Non-toxic, biocompatible
- Non-immunogenic
- Soluble agents
Becoming an advantageous platform for delivering therapeutic agents |
Polymer-based nanocarriers | - Solid, biodegradable colloidal systems that have been widely studied as drugs or gene carriers
- PEI polymers are the best polymer-based nanoparticles for siRNA delivery due to their positive charge, molecular weight, and special branching patterns
|
Dendrimers | - Extremely high stability
- Water solubility
- Reduced antigenicity
|
Inorganic Nanocarriers | |
Gold nanocarriers | Over the years, gold nanoparticles have been extensively studied as the ultimate candidate for siRNA |
Iron oxide nanocarriers | - Excellent cell absorption
- Stable and modifiable
- The same thermal activation properties as gold nanoparticles
- Unique magnetic properties
External magnetic fields can be used to improve the delivery of siRNA and/or therapeutic compounds to improve the cancer treatment effect |
For different applications, each conjugate has special requirements, including siRNA sequence and modification, nanoparticle size, charge, and chemical modification. At BOC RNA, we are committed to providing one-to-one technical support to ensure that each customer is completely satisfied and gets the best results.
BOC Sciences' Nanoparticle siRNA Delivery Solution
- RNA (siRNA / miRNA) Synthesis
- Choosing the best size nanoparticles
- Cross-linking siRNA to selected size nanoparticles
Why Choose Us?
- Using our unique expertise in bioconjugation chemistry, we ensure the production of high-quality conjugates.
- High-quality, well-defined conjugates
- Flexible service options
- Experience and competence of a dedicated team
Figure 1: Scheme showing the different types of nanoparticles used in drug delivery for the treatment of the various types of cancers (Rasha Itani. 2019).
Figure 2: Mechanism of action of siRNA conjugated nanoparticle (Acharya, R. 2017).
References:
- Halbur, C. et al. siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer. SLAS TECHNOLOGY: Translating Life Sciences Innovation. 2019; 24(2):137-150.
- Jong-Min Lee. et al. Recent Developments in Nanoparticle-Based siRNA Delivery for Cancer Therapy. BioMed Research International. 2013; 2013:782041.
- Rasha Itani &Achraf Al Faraj. siRNA Conjugated Nanoparticles—A Next Generation Strategy to Treat Lung Cancer. Int. J. Mol. Sci. 2019; 20(23):6088.
- Rituparna Acharya. et al. siRNA-nanoparticle conjugate in gene silencing: A future cure to deadly diseases? Materials Science and Engineering: C. 2017; 76:1378-1400.
* Only for research. Not suitable for any diagnostic or therapeutic use.